Molnupiravir (EIDD-2801) 是核糖核苷类似物 EIDD-1931 的口服生物可利用的异丙酯前药。Molnupiravir 显示出广泛的抗流感病毒 (influenza virus) 和冠状病毒 (coronaviruses) 的活性，如 SARS-CoV-2，MERS-CoV，SARS-CoV。Molnupiravir 有用于 COVID-19 和季节性，流行性流感的潜力。
货号:ajcx33176
CAS:2492423-29-5;2349386-89-4
分子式:C13H19N3O7
分子量：329.31
溶解度:DMSO : 100 mg/mL (303.67 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存： 现货

Background:

Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

Molnupiravir (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease[1].Molnupiravir (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever[2].

[1]. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.
[2]. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.